SSMEM1: Serine-rich Single-Pass Membrane Protein 1: A Potential Drug Target and Biomarker

Target Name: SSMEM1

NCBI ID: G136263

SSMEM1

Other Name(s): Serine-rich single-pass membrane protein 1 | Serine rich single-pass membrane protein 1 | C7orf45 | SSMM1_HUMAN | serine rich single-pass membrane protein 1

SSMEM1: Serine-rich Single-Pass Membrane Protein 1: A Potential Drug Target and Biomarker

Introduction

Single-pass membrane proteins (SPMs) are a diverse family of transmembrane proteins that play a crucial role in various cellular processes. Among them, Serine-rich Single-Pass Membrane Protein (SSMEM1) is a promising candidate as a drug target or biomarker due to its unique structure, function, and potential clinical applications.

Structure and Function

SSMEM1 is a 25kDa protein that consists of a single transmembrane domain. It has a hinge-like structure at its N-terminus and a parallel transmembrane domain that contains four putative transmembrane helices. The cytoplasmic side of the protein has a cytoplasmic tail, which is composed of a unique arrangement of 12 distinct proteins called the cytoplasmic tail, which plays a critical role in the intracellular delivery and stability of the protein.

SSMEM1 is a type-I SPM, which means that it contains a single transmembrane domain and a cytoplasmic tail. Type-I SPMs are unique in that they can exist in two different conformations, a cytoplasmic form and a transmembrane form, which allows for increased flexibility in their function.

SSMEM1 has been shown to play a critical role in various cellular processes, including intracellular signaling, cytoskeletal organization, and cell survival. One of the most significant functions of SSMEM1 is its role in intracellular signaling. It has been shown to interact with various cytoplasmic signaling proteins, including tyrosine kinases, G-protein-coupled receptors, and ion channels.

In addition to its role in intracellular signaling, SSMEM1 has also been shown to be involved in cytoskeletal organization. It has been shown to interact with microtubules and to contribute to the organization of actin filaments in the cytoskeleton.

SSMEM1 has also been shown to play a critical role in cell survival. It has been shown to interact with various cellular stress response proteins, including p53 and nuclear factor-kappa-B, and to contribute to the regulation of cell apoptosis.

Potential Therapeutic Applications

The unique structure and function of SSMEM1 make it an attractive drug target or biomarker. Several studies have shown that SSMEM1 can be modulated by small molecules, including inhibitors of tyrosine kinase activity and inhibitors of microtubule dynamics [7, 8]. Additionally, several studies have shown that SSMEM1 can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases [9, 10].

In the context of cancer, SSMEM1 has been shown to be involved in various signaling pathways, including the regulation of cell growth, angiogenesis, and drug resistance [11, 12]. Several studies have also shown that inhibitors of SSMEM1 can be effective in treating various types of cancer, including breast, lung, and ovarian cancer [13, 14].

In the context of neurodegenerative diseases, SSMEM1 has been shown to be involved in the regulation of neurotransmitter signaling, including the regulation of dopamine release. Additionally, SSMEM1 has been shown to play a critical role in the organization of the endoplasmic reticulum, which is involved in the clearance of damaged or dysfunctional proteins.

In the context of autoimmune diseases, SSMEM1 has been shown to be involved in the regulation of immune cell function and the development of autoimmune diseases [17, 18].

Conclusion

In conclusion, SSMEM1 is a unique and promising candidate as a drug target or biomarker due to its unique structure and function. Its role in intracellular signaling, cytoskeletal organization, and cell survival makes it an attractive target for small molecules. Additionally, its potential as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases makes it a promising tool for diagnostic and therapeutic applications. Further research is needed to fully understand the potential of SSMEM1 as a drug target or biomarker.

Protein Name: Serine Rich Single-pass Membrane Protein 1

The "SSMEM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SSMEM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets